BridgeBio Pharma, Inc.

BBIO · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.9%

Institutions99.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$502.08M	$221.90M	$77.65M	$69.72M	$8.25M	$40.56M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$20.96M	$3.88M	–	$2.73M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$523.41M	-$592.97M	-$512.20M	-$576.63M	-$474.48M	-$266.24M
Operating income as a percentage of revenue.	-104.2%	-267.2%	-659.6%	-827.1%	-5752.0%	-656.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$8.01M	-$7.58M	-$3.47M	-$23.91M	-$56.76M	-$28.00M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-2.00	$-3.00	$-3.90	$-3.80	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-2.00	$-3.00	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$570.12M	$681.10M	$376.69M	$393.77M	$356.08M	$363.77M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$936.02M	$919.34M	$623.04M	$1.01B	$703.59M	$631.68M
All of the company's interest-bearing borrowings, short and long term combined.	$1.85B	$437.34M	$430.99M	$430.75M	$93.88M	$91.79M
Everything the company owes — debt, unpaid bills, and other obligations.	$3.01B	$2.38B	$1.87B	$1.88B	$595.70M	$155.70M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$2.09B	-$1.47B	-$1.25B	-$870.41M	$57.91M	$408.45M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$445.91M	-$520.73M	-$419.49M	-$497.93M	-$399.71M	-$253.59M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.10M	$933000	$4.82M	$13.25M	$7.52M	$2.64M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$447.01M	-$521.66M	-$424.31M	-$511.18M	-$407.23M	-$256.23M

	You	Peer avg
P/E	–	18.9
Revenue Growth	+120.4%	+92.8%
ROE	–	-3.8%

BridgeBio Pharma, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison